Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD46 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD46 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD46 Products |
| Gene Delivery | CD46 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD46 Products |
| Benchmark Ab | Anti-CD46 (Sequence of FOR46) Recombinant positive control. |
View CD46 Products |
| Validator | CD46 siRNA Set For knockdown verification. |
View CD46 Products |
| Related Target A | PSMA Synergistic target for prostate cancer (mCRPC) combination therapies. |
View PSMA Products |
| Related Target B | BCMA Alternative target for multiple myeloma resistance bypass. |
View BCMA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Internalization validation for ADCs | HEK293 Expressed (Native Glycosylation) ECD-Fc fusions for accurate binding kinetics |
| Membrane conformation preservation | Lentivirus Premade Particles for stable cell line construction |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD46 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD46 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting metastatic castration-resistant prostate cancer (mCRPC) and multiple myeloma, utilizing highly specific epitopes to minimize healthy tissue toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Fortis Therapeutics | mCRPC, Multiple Myeloma | Internalization Assay (Need high-purity ECD-Fc) |
| CAR-T | Academic/Biotech | Hematological Malignancies | Cell Line Construction (Need Lentivirus) |
| Bispecific | Emerging Biopharma | Solid Tumors | Heterodimer Validation (Need Cross-reactive Abs) |